Di Zhu
8PUBLICATIONS
26CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Nov 17, 2025
Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.Sui-Yi Wu, Yuan-Yuan Zhu, Jia-Lei Sun
|May 29, 2024
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration.Fenglian He, Zhongen Wu, Chenglong Liu
|Apr 23, 2022
RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers.Li Xia, Enming Tian, Mingcheng Yu
|Apr 12, 2022
IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment.Bo Hu, Mincheng Yu, Xiaolu Ma
|Apr 14, 2021
Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.Hao Zhang, Ya Bao, Chenglong Liu
|Mar 26, 2021
BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.Xiaoshuang Wang, Mei Feng, Tengfei Xiao
Pageof 2
